BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics Corp. is set to make significant contributions at the 2024 ASCO Annual Meeting with an oral presentation by Dr. Saranya Chumsri on Phase 2 clinical data of Bria-IMT™ in advanced metastatic breast cancer, and two poster presentations highlighting ongoing studies and clinical data on Bria-IMT™ in patients who have not responded to antibody drug conjugates. The company’s latest research endeavors underscore its commitment to advancing cancer immunotherapy treatments.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
